76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Penumbra Inc
Closed
SectorHealthcare
258.69 0.36
Overview
Share price change
24h
Min
256.03
Max
261.14
Income | 5.5M 39M |
|---|---|
Sales | 8.6M 324M |
P/E Sector Avg | 237.185 51.198 |
EPS | 0.83 |
Profit margin | 12.101 |
Employees | 4,500 |
EBITDA | 131K 49M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +23.69% upside |
Next Earnings | 29 Jul 2025 |
|---|
Market Cap | -809M 9.9B |
|---|---|
Previous open | 258.33 |
Previous close | 258.69 |
News Sentiment
By Acuity
50%
50%
167 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Penumbra Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Penumbra Inc Forecast
Price Target
By TipRanks
23.69% upside
12 Months Forecast
Average 319.58 USD 23.69%
High 340 USD
Low 260 USD
Based on 16 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.
Sentiment
By Acuity
167 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
